 In this trial, ALRN-6924 is being evaluated as an agent to protect patients against chemotherapy-induced toxicity, a concept known as chemoprotection or myelopreservation. Patients in the trial have advanced, p53-mutated small cell lung cancer SCLC and are being treated with second-line topotecan following administration of ALRN-6924. 